MY197560A - Pulmonary delivery of progestogen - Google Patents

Pulmonary delivery of progestogen

Info

Publication number
MY197560A
MY197560A MYPI2018701112A MYPI2018701112A MY197560A MY 197560 A MY197560 A MY 197560A MY PI2018701112 A MYPI2018701112 A MY PI2018701112A MY PI2018701112 A MYPI2018701112 A MY PI2018701112A MY 197560 A MY197560 A MY 197560A
Authority
MY
Malaysia
Prior art keywords
formulation
ohpc
powder
diseases
mapk
Prior art date
Application number
MYPI2018701112A
Other languages
English (en)
Inventor
Chang Lee
Tao Tom Du
Original Assignee
Shenzhen Evergreen Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/860,578 external-priority patent/US10993879B2/en
Application filed by Shenzhen Evergreen Therapeutics Co Ltd filed Critical Shenzhen Evergreen Therapeutics Co Ltd
Publication of MY197560A publication Critical patent/MY197560A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2018701112A 2015-09-21 2016-09-21 Pulmonary delivery of progestogen MY197560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/860,578 US10993879B2 (en) 2010-02-08 2015-09-21 Pulmonary delivery of progestogen
PCT/US2016/052858 WO2017053409A1 (en) 2015-09-21 2016-09-21 Pulmonary delivery of progestogen

Publications (1)

Publication Number Publication Date
MY197560A true MY197560A (en) 2023-06-23

Family

ID=58387175

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018701112A MY197560A (en) 2015-09-21 2016-09-21 Pulmonary delivery of progestogen

Country Status (4)

Country Link
EP (1) EP3344338A4 (ja)
JP (1) JP6693009B2 (ja)
MY (1) MY197560A (ja)
WO (1) WO2017053409A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939272A1 (en) 2019-03-12 2022-01-19 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Encoders, decoders, methods, and video bit streams, and computer programs for hybrid video coding

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504097A (ja) * 2004-07-01 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ナノ粒子を含有する医薬組成物の調製
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Also Published As

Publication number Publication date
EP3344338A1 (en) 2018-07-11
JP6693009B2 (ja) 2020-05-13
EP3344338A4 (en) 2019-05-08
WO2017053409A1 (en) 2017-03-30
JP2018534347A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
TN2017000226A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
WO2020086759A3 (en) Composition and method for treating the lungs
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2019003988A (es) Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
MY192532A (en) Liquid pharmaceutical composition
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
MX370890B (es) Composición que comprende sulfato de salbutamol.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
WO2018094300A8 (en) ANTI-GITR ANTIGEN BINDING PROTEINS AND METHODS OF USE
MX2021005085A (es) Formulacion de anticuerpo.